BiotechTube

DS3790a + Combination drug + Combination drug

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hematological Malignancies

Conditions

Hematological Malignancies

Trial Timeline

Jan 16, 2026 → Nov 30, 2030

NCT ID
NCT07220616

About DS3790a + Combination drug + Combination drug

DS3790a + Combination drug + Combination drug is a phase 1/2 stage product being developed by Daiichi Sankyo for Hematological Malignancies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07220616. Target conditions include Hematological Malignancies.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07220616Phase 1/2Recruiting

Competing Products

20 competing products in Hematological Malignancies

See all competitors
ProductCompanyStageHype Score
isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oralAstellas PharmaPhase 1
33
Capivasertib + RabeprazoleAstraZenecaPhase 1
33
AZD9829 + AZD9829AstraZenecaPhase 1/2
41
Pembrolizumab/vibostolimab coformulationMerckPhase 2
52
NemtabrutinibMerckPhase 1
33
NemtabrutinibMerckPhase 1
33
Study Part 1: KRP203 + Study Part 2: KRP203 lower dose + Study Part 2: KRP203 higher doseNovartisPhase 1
33
LBH589NovartisPhase 1
33
HDM201 + ancillary treatmentNovartisPhase 1
33
Ibandronate + Vitamin SupplementsRochePhase 3
77
Darbepoetin alpha (Aranesp) + Iron saccharate (Venofer)AmgenPhase 2/3
64
Axicabtagene Ciloleucel + Brexucabtagene Autoleucel + Anitocabtagene autleucel + KITE-753 + KITE-197 + KITE-363Gilead SciencesPre-clinical
22
Magrolimab + AzacitidineGilead SciencesPhase 1
32
piperacillin-tazobactam + glycopeptidePfizerPre-clinical
22
Isatuximab SAR650984 + Dexamethasone + DexamethasoneSanofiPhase 1/2
40
Thymoglobulin Injectable ProductSanofiPhase 2
51
ATG + Post-transplantation cyclophosphamideSanofiPre-clinical
22
Mycophenolate Mofetil (MMF) + Thymoglobulin + SirolimusSanofiPhase 2
51
Rituximab + 375 mg/m2 RRituximabBiogenPhase 1/2
38
HMPL-506HUTCHMEDPhase 1
28

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85